Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.
Manuel Sousa J, Vergara M, Pulido F, Sánchez Antolín G, Hijona L, Carnicer F, Rincón D, Salmerón J, Mateos-Muñoz B, Jou A, Polo-Lorduy B, Rubín Á, Escarda A, Aguilar P, Aldámiz-Echevarría T, García-Buey L, Carrión JA, Hernández-Guerra M, Chimeno-Hernández S, Espinosa N, Morillas RM, Andrade RJ, Delgado M, Gallego A, Magaz M, Moreno-Planas JM, Estébanez Á, Rico M, Menéndez F, Sampedro B, Morano L, Izquierdo S, Zozaya JM, Rodríguez M, Morán-Sánchez S, Lorente S, Martín-Granizo I, Von-Wichmann MÁ, Delgado M, Manzanares A. Manuel Sousa J, et al. Among authors: pulido f. PLoS One. 2019 Nov 12;14(11):e0225061. doi: 10.1371/journal.pone.0225061. eCollection 2019. PLoS One. 2019. PMID: 31714950 Free PMC article.
Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Berenguer J, González-García J, López-Aldeguer J, Von-Wichmann MA, Quereda C, Hernando A, Sanz J, Tural C, Ortega E, Mallolas J, Santos I, Miralles P, Montes ML, Bellón JM, Esteban H; GESIDA HIV/HCV cohort. Berenguer J, et al. J Antimicrob Chemother. 2009 Jun;63(6):1256-63. doi: 10.1093/jac/dkp106. Epub 2009 Apr 10. J Antimicrob Chemother. 2009. PMID: 19363085 Clinical Trial.
Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus.
Berenguer J, von Wichmann MA, Quereda C, Miralles P, Mallolas J, López-Aldeguer J, Alvarez-Pellicer J, De Miguel J, Crespo M, Guardiola JM, Tellez MJ, Galindo MJ, Arponen S, Barquilla E, Bellón JM, González-García J; GESIDA 36/03 and 50/06 Study Groups. Berenguer J, et al. J Antimicrob Chemother. 2011 Dec;66(12):2843-9. doi: 10.1093/jac/dkr362. Epub 2011 Sep 29. J Antimicrob Chemother. 2011. PMID: 21965432
Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.
Berenguer J, Rodríguez E, Miralles P, Von Wichmann MA, López-Aldeguer J, Mallolas J, Galindo MJ, Van Den Eynde E, Téllez MJ, Quereda C, Jou A, Sanz J, Barros C, Santos I, Pulido F, Guardiola JM, Ortega E, Rubio R, Jusdado JJ, Montes ML, Gaspar G, Esteban H, Bellón JM, González-García J; GESIDA HIV/HCV Cohort Study Group. Berenguer J, et al. Among authors: pulido f. Clin Infect Dis. 2012 Sep;55(5):728-36. doi: 10.1093/cid/cis500. Epub 2012 May 18. Clin Infect Dis. 2012. PMID: 22610932
Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus.
Berenguer J, Alvarez-Pellicer J, Carrero A, Von Wichmann MA, López-Aldeguer J, Mallolas J, Galindo MJ, Van Den Eynde E, Téllez MJ, Quereda C, Tural C, Sanz J, Barros C, Santos I, Pulido F, Guardiola JM, Ortega E, Rubio R, Jusdado JJ, Montes ML, Gaspar G, Barquilla E, Bellón JM, González-García J; GESIDA HIV/HCV Cohort Study Group. Berenguer J, et al. Among authors: pulido f. J Hepatol. 2013 Jun;58(6):1104-12. doi: 10.1016/j.jhep.2013.01.042. Epub 2013 Feb 7. J Hepatol. 2013. PMID: 23395690
Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus.
Berenguer J, Zamora FX, Aldámiz-Echevarría T, Von Wichmann MA, Crespo M, López-Aldeguer J, Carrero A, Montes M, Quereda C, Téllez MJ, Galindo MJ, Sanz J, Santos I, Guardiola JM, Barros C, Ortega E, Pulido F, Rubio R, Mallolas J, Tural C, Jusdado JJ, Pérez G, Díez C, Álvarez-Pellicer J, Esteban H, Bellón JM, González-García J; Grupo de Estudio del SIDA (GESIDA) HIV/HCV Cohort Study Group. Berenguer J, et al. Among authors: pulido f. Clin Infect Dis. 2015 Mar 15;60(6):950-8. doi: 10.1093/cid/ciu939. Epub 2014 Nov 24. Clin Infect Dis. 2015. PMID: 25422386
Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection.
Berenguer J, Rodríguez-Castellano E, Carrero A, Von Wichmann MA, Montero M, Galindo MJ, Mallolas J, Crespo M, Téllez MJ, Quereda C, Sanz J, Barros C, Tural C, Santos I, Pulido F, Guardiola JM, Rubio R, Ortega E, Montes ML, Jusdado JJ, Gaspar G, Esteban H, Bellón JM, González-García J; GESIDA HIV/HCV Cohort Study Group. Berenguer J, et al. Among authors: pulido f. Hepatology. 2017 Aug;66(2):344-356. doi: 10.1002/hep.29071. Epub 2017 Jun 22. Hepatology. 2017. PMID: 28109003 Free PMC article.
Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
Sulkowski MS, Fessel WJ, Lazzarin A, Berenguer J, Zakharova N, Cheinquer H, Côté P, Dieterich D, Gadano A, Matthews G, Molina JM, Moreno C, Pineda JA, Pulido F, Rivero A, Rockstroh J, Hernandez D, McPhee F, Eley T, Liu Z, Mendez P, Hughes E, Noviello S, Ackerman P. Sulkowski MS, et al. Among authors: pulido f. Hepatol Int. 2017 Mar;11(2):188-198. doi: 10.1007/s12072-017-9788-z. Epub 2017 Feb 16. Hepatol Int. 2017. PMID: 28210927 Clinical Trial.
Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults.
Pérez-Molina JA, Martínez E, Blasco AJ, Arribas JR, Domingo P, Iribarren JA, Knobel H, Lázaro P, López-Aldeguer J, Lozano F, Mariño A, Miró JM, Moreno S, Negredo E, Pulido F, Rubio R, Santos J, de la Torre J, Tuset M, von Wichmann MA, Gatell JM. Pérez-Molina JA, et al. Among authors: pulido f. Enferm Infecc Microbiol Clin (Engl Ed). 2019 Mar;37(3):151-159. doi: 10.1016/j.eimc.2018.04.010. Epub 2018 Jun 6. Enferm Infecc Microbiol Clin (Engl Ed). 2019. PMID: 29884455 English, Spanish.
335 results